INmune Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . INmune Bio
INMB Stock  USD 1.51  0.09  6.34%   
INmune Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing INmune Bio's valuation are provided below:
Gross Profit
50 K
Market Capitalization
37.8 M
Enterprise Value Revenue
277.7704
Revenue
50 K
Earnings Share
(1.94)
We have found one hundred twenty available fundamental trends for INmune Bio, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of INmune Bio regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

INmune Bio Total Revenue

11,970

Check INmune Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among INmune Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 604.2 K, Interest Expense of 1.6 M or Selling General Administrative of 6.8 M, as well as many indicators such as Price To Sales Ratio of 6.1 K, Dividend Yield of 0.0 or PTB Ratio of 2.74. INmune financial statements analysis is a perfect complement when working with INmune Bio Valuation or Volatility modules.
  
Build AI portfolio with INmune Stock
Check out the analysis of INmune Bio Correlation against competitors.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

INmune Bio Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets41.8 M45.5 M27.5 M
Slightly volatile
Total Current Liabilities5 M8.3 M3.4 M
Slightly volatile
Accounts Payable7.9 M7.5 M2.5 M
Slightly volatile
Cash23.6 M24.1 M15.4 M
Slightly volatile
Cash And Short Term Investments23.6 M24.1 M15.4 M
Slightly volatile
Common Stock Shares Outstanding13.9 M22.9 M11.1 M
Slightly volatile
Liabilities And Stockholders Equity41.8 M45.5 M27.5 M
Slightly volatile
Capital Surpluse183.3 M174.6 M65.8 M
Slightly volatile
Other Stockholder Equity236.4 M225.1 M74.9 M
Slightly volatile
Total Liabilities7.9 M8.6 M5.2 M
Slightly volatile
Total Current Assets26.9 M26.1 M17.5 M
Slightly volatile
Common Stock24 K25.3 K58.8 K
Slightly volatile
Short and Long Term Debt Total419.5 K441.6 K2.7 M
Slightly volatile
Net Receivables2.6 M1.6 M1.6 M
Slightly volatile
Common Stock Total Equity12.9 K20.7 K10.7 K
Slightly volatile
Other Current Assets283 K297.9 K46.3 M
Very volatile
Short and Long Term Debt12 M11.4 M4.5 M
Slightly volatile
Short Term Debt152.9 K161 K1.1 M
Slightly volatile
Net Invested Capital47.7 M36.9 M32.8 M
Slightly volatile
Net Working Capital27.5 M17.8 M15.1 M
Slightly volatile
Intangible Assets13.2 M14.9 M16.2 M
Slightly volatile
Capital Stock24 K25.3 K60.4 K
Slightly volatile
Property Plant And Equipment Net421.9 K353.1 K282.4 K
Slightly volatile
Capital Lease Obligations479.9 K441.6 K297.4 K
Slightly volatile
Property Plant And Equipment Gross422 K353.1 K282.4 K
Slightly volatile
Non Current Liabilities Other623 K1.2 M454.1 K
Slightly volatile
Property Plant Equipment434.7 K583 K313.9 K
Slightly volatile
Other Assets0.860.9112.7 K
Slightly volatile
Other Liabilities411.9 K632.5 K299 K
Slightly volatile
Long Term Debt9.7 M8.7 M13 M
Slightly volatile
Long Term Debt Total9.7 M8.7 M13 M
Slightly volatile

INmune Bio Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative6.8 M10.9 M4.7 M
Slightly volatile
Selling And Marketing Expenses108.6 K187.4 K118.4 K
Very volatile
Other Operating Expenses51.5 M49 M15.5 M
Slightly volatile
Research Development40 M38.1 M10.6 M
Slightly volatile
Total Operating Expenses51.5 M49 M15.5 M
Slightly volatile
Net Interest Income62.2 K69.9 K76.3 K
Slightly volatile
Interest Income62.2 K69.9 K76.3 K
Slightly volatile

INmune Bio Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.4 M8.7 M3.5 M
Slightly volatile
End Period Cash Flow23.6 M24.1 M15.4 M
Slightly volatile
Change To Netincome8.6 M8.2 M3.6 M
Slightly volatile
Begin Period Cash Flow23.6 M41.2 M15.2 M
Slightly volatile
Issuance Of Capital Stock23.2 M32 M12.3 M
Slightly volatile
Depreciation216 K257.6 K157.2 K
Slightly volatile
Change Receivables183.2 K206.1 K225 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.1 K7.7 K13.5 K
Slightly volatile
Days Sales Outstanding34.7 K33.1 K14.8 K
Slightly volatile
Average Payables455.4 K864 K557 K
Slightly volatile
Stock Based Compensation To Revenue513489114
Slightly volatile
EV To Sales5.3 K6 K11.9 K
Slightly volatile
Sales General And Administrative To Revenue640610493
Slightly volatile
Research And Ddevelopement To Revenue228150395
Slightly volatile
Capex To Revenue78.3174.5928.4939
Slightly volatile
Cash Per Share1.060.940.899
Slightly volatile
Income Quality0.560.710.5955
Slightly volatile
Intangibles To Total Assets0.550.480.6654
Slightly volatile
Current Ratio5.052.824.2866
Slightly volatile
Receivables Turnover0.01090.01140.0314
Pretty Stable
Capex Per Share0.880.840.3242
Slightly volatile
Revenue Per Share8.0E-48.0E-40.0031
Slightly volatile
Interest Debt Per Share0.01650.01730.1749
Slightly volatile
Debt To Assets0.01060.01120.3532
Slightly volatile
Operating Cycle34.7 K33.1 K14.8 K
Slightly volatile
Ebt Per Ebit1.121.141.1004
Slightly volatile
Long Term Debt To Capitalization0.170.160.1517
Very volatile
Total Debt To Capitalization0.01290.01360.7554
Slightly volatile
Quick Ratio3.433.6168.9096
Very volatile
Cash Ratio4.352.613.7236
Slightly volatile
Cash Conversion Cycle34.7 K33.1 K14.8 K
Slightly volatile
Days Of Sales Outstanding34.7 K33.1 K14.8 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.981.371.2062
Slightly volatile
Fixed Asset Turnover0.0390.0410.1331
Slightly volatile
Debt Ratio0.01060.01120.3532
Slightly volatile
Price Sales Ratio6.1 K7.7 K13.5 K
Slightly volatile
Asset Turnover3.0E-43.0E-48.0E-4
Slightly volatile

INmune Bio Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap32.3 M36.7 M39.8 M
Slightly volatile
Enterprise Value32.4 M36.9 M39.9 M
Slightly volatile

INmune Fundamental Market Drivers

INmune Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About INmune Bio Financial Statements

INmune Bio stakeholders use historical fundamental indicators, such as INmune Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although INmune Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in INmune Bio's assets and liabilities are reflected in the revenues and expenses on INmune Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in INmune Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue562.4 K323.7 K
Total Revenue12.6 K12 K
Stock Based Compensation To Revenue 488.89  513.34 
Sales General And Administrative To Revenue 609.62  640.10 
Research And Ddevelopement To Revenue 150.41  227.66 
Capex To Revenue 74.59  78.31 
Ebit Per Revenue-3.5 K-3.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
How To Invest In INmune
Details
Is INmune Stock a good investment?
Details
What is INmune Bio's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of INmune Bio Correlation against competitors.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. Market participants price INmune higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive INmune Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.94)
Revenue Per Share
0.002
Quarterly Revenue Growth
2.571
Return On Assets
(0.51)
Return On Equity
(1.56)
INmune Bio's market price often diverges from its book value, the accounting figure shown on INmune's balance sheet. Smart investors calculate INmune Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since INmune Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY